<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158845</url>
  </required_header>
  <id_info>
    <org_study_id>SIU-LNG 001</org_study_id>
    <nct_id>NCT02158845</nct_id>
  </id_info>
  <brief_title>Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis</brief_title>
  <acronym>SIU-LNG</acronym>
  <official_title>Effects of the Levonorgestrel-releasing Intrauterine System Compared With the Leuprolide Acetate in Patients With Endometriosis: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hemostatic and inflammatory systems may activate each other. Endometriosis is a chronic
      inflammatory disease affecting 10% of women. The objective of this study is to compare the
      hemostatic effects of two treatments widely prescribed to women with endometriosis: the
      levonorgestrel intrauterine system (LNG-IUS) and the gonadotropin-releasing hormone analog
      (GnRHa) leuprolide acetate.

      Hypothesis:

      H0: There is no alteration in hemostatic system with the use of GnRHa or LNG-IUS H1: There is
      alteration in hemostatic system with the use of GnRHa or LNG-IUS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Materials and Methods: In this randomized open-label controlled trial, 44 women with
      endometriosis will be randomly allocated to one of two groups: 22 women will be assigned to
      use LNG-IUS and 22 to use GnRHa. The assessed variables will be D-dimers, fibrinogen,
      prothrombin time, activated partial thromboplastin time, coagulation factors (F) II, V, VII,
      VIII, IX, X, and XI, antithrombin (AT), protein C, free protein S, tissue plasminogen
      activator (t-PA), α2-antiplasmin, thrombin-antithrombin complex, and prothrombin fragment
      1+2. All variables will be assessed before treatment and six months after treatment onset.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in d-dimer</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>to compare the change over 6 months (6 months - baseline) on d-dimer of two treatments widely prescribed to women with endometriosis, LNG-IUS and GnRHa leuprolide acetate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in Coagulation times</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>To compare the change over 6 months (6 months - baseline) of coagulation times as a composite measure of 3 variables: Thrombin time (TT), activated partial thromboplastin time (APTT), and prothrombin time (PT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in procoagulatory variables</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>to compare the change over 6 months (6 months - baseline) on procoagulatory variables (Fibrinogen, coagulation factors II, V, VII, VIII, IX, X, and XI) of two treatments widely prescribed to women with endometriosis, LNG-IUS and GnRHa leuprolide acetate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in natural anticoagulants</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>to compare the change over 6 months (6 months - baseline) on natural anticoagulants (Protein C and antithrombin) of two treatments widely prescribed to women with endometriosis, LNG-IUS and GnRHa leuprolide acetate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activation of the coagulation cascade markers</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>to compare the change over 6 months (6 months - baseline) on activation of the coagulation cascade markers (concentrations of the thrombin-antithrombin complex and prothrombin fragment 1+2) of two treatments widely prescribed to women with endometriosis, LNG-IUS and GnRHa leuprolide acetate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on antifibrinolytic variables</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>to compare the change over 6 months (6 months - baseline) on antifibrinolytic variables (Plasminogen activator inhibitor 1, α-2 antiplasmin) of two treatments widely prescribed to women with endometriosis, LNG-IUS and GnRHa leuprolide acetate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>LNG-IUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LNG-IUS: levonorgestrel intrauterine system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRHa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GnRHa: leuprolide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNG-IUS: levonorgestrel intrauterine system</intervention_name>
    <description>LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG</description>
    <arm_group_label>LNG-IUS</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRHa: leuprolide</intervention_name>
    <description>3.75 mg leuprolide injected intramuscularly on a monthly basis</description>
    <arm_group_label>GnRHa</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  to have endometriosis

          -  aged 18 to 40 years

          -  Being without contraceptives for at least 3 months or with depot medroxyprogesterone
             acetate or GnRHa for at least 6 months at the time of randomization.

        Exclusion Criteria:

          -  obese patients with a body mass index (BMI) ≥30 kg/m2

          -  smokers

          -  diabetics

          -  alcohol or drug users

          -  patients currently wishing to conceive

          -  patients with chronic diseases (except endometriosis)

          -  patients with infectious processes

          -  patients with a personal and/or family history of thromboembolic events

          -  patients taking medications known to interfere with inflammation markers (such as
             hormonal and nonhormonal anti-inflammatory agents) within the 15 days before the
             study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CAROLINA S VIEIRA, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sao Paulo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clinica de Ribeirao Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>SP</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Yamaguti EM, Brito MB, Ferriani RA, Garcia AA, Rosa-e-Silva JC, Vieira CS. Comparison of the hemostatic effects of a levonorgestrel-releasing intrauterine system and leuprolide acetate in women with endometriosis: a randomized clinical trial. Thromb Res. 2014 Dec;134(6):1193-7. doi: 10.1016/j.thromres.2014.09.014. Epub 2014 Sep 20.</citation>
    <PMID>25283586</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>January 17, 2015</last_update_submitted>
  <last_update_submitted_qc>January 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Carolina Sales Vieira</investigator_full_name>
    <investigator_title>Medical Doctor, PhD</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>blood coagulation</keyword>
  <keyword>levonorgestrel</keyword>
  <keyword>GnRH agonist</keyword>
  <keyword>progesterone-releasing intrauterine device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

